In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $23.00. The company's shares closed last Thursday at $19.51. According to TipRanks.com, Butler 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.9% and a 38.0% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and Minerva Neurosciences. Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $27.17, a 39.4% upside from current levels.
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-rating-from-jmp-securities?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.